{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:39:19Z","timestamp":1767890359868,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10067-018-04406-z","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T22:23:33Z","timestamp":1547072613000},"page":"1309-1317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Vincenzo","family":"Venerito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Cacciapaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"issue":"2 Suppl 1","key":"4406_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200422001-00002","volume":"22","author":"TK Kvien","year":"2004","unstructured":"Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):1\u201312","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"4406_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/03009740500327727","volume":"34","author":"TK Kvien","year":"2005","unstructured":"Kvien TK, Uhlig T (2005) Quality of life in rheumatoid arthritis. Scand J Rheumatol 34(5):333\u2013341. \n                    https:\/\/doi.org\/10.1080\/03009740500327727","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"4406_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/BOR.0b013e32835fc62e","volume":"25","author":"I Navarro-Millan","year":"2013","unstructured":"Navarro-Millan I, Curtis JR (2013) Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 25(3):384\u2013390. \n                    https:\/\/doi.org\/10.1097\/BOR.0b013e32835fc62e","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"4406_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/annrheumdis-2014-206993","volume":"74","author":"K Raza","year":"2015","unstructured":"Raza K, Filer A (2015) The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? Ann Rheum Dis 74(5):793\u2013794. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-206993","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4406_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.autrev.2012.11.010","volume":"12","author":"OM Epis","year":"2013","unstructured":"Epis OM, Giacomelli L, Deidda S, Bruschi E (2013) Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 12(8):839\u2013841. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2012.11.010","journal-title":"Autoimmun Rev"},{"issue":"2","key":"4406_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3899\/jrheum.110967","volume":"39","author":"H Zeidler","year":"2012","unstructured":"Zeidler H (2012) The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol 39(2):212\u2013217. \n                    https:\/\/doi.org\/10.3899\/jrheum.110967","journal-title":"J Rheumatol"},{"issue":"9","key":"4406_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580\u20131588. \n                    https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"issue":"10055","key":"4406_CR8","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8","journal-title":"Lancet"},{"issue":"5","key":"4406_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.autrev.2012.10.020","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Benucci M, Salli S, Bongiovanni S, Boccassini L, Sarzi-Puttini P (2013) Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 12(5):575\u2013579. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2012.10.020","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4406_CR10","first-page":"347","volume":"36","author":"A Bortoluzzi","year":"2018","unstructured":"Bortoluzzi A, Furini F, Generali E, Silvagni E, Luciano N, Scire CA (2018) One year in review 2018: novelties in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 36(3):347\u2013361","journal-title":"Clin Exp Rheumatol"},{"key":"4406_CR11","doi-asserted-by":"publisher","first-page":"CD012591","DOI":"10.1002\/14651858.CD012591","volume":"3","author":"JA Singh","year":"2017","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, Lopez-Olivo MA, Suarez-Almazor ME, Tugwell P, Wells GA (2017) Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev 3:CD012591. \n                    https:\/\/doi.org\/10.1002\/14651858.CD012591","journal-title":"Cochrane Database Syst Rev"},{"key":"4406_CR12","doi-asserted-by":"publisher","first-page":"CD012183","DOI":"10.1002\/14651858.CD012183","volume":"5","author":"JA Singh","year":"2016","unstructured":"Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 5:CD012183. \n                    https:\/\/doi.org\/10.1002\/14651858.CD012183","journal-title":"Cochrane Database Syst Rev"},{"key":"4406_CR13","doi-asserted-by":"publisher","first-page":"CD012657","DOI":"10.1002\/14651858.CD012657","volume":"5","author":"JA Singh","year":"2017","unstructured":"Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, Maxwell LJ, Tugwell P, Wells GA (2017) Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev 5:CD012657. \n                    https:\/\/doi.org\/10.1002\/14651858.CD012657","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4406_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40259-016-0164-7","volume":"30","author":"A Migliore","year":"2016","unstructured":"Migliore A, Bizzi E, Petrella L, Bruzzese V, Cassol M, Integlia D (2016) The challenge of treating early-stage rheumatoid arthritis: the contribution of mixed treatment comparison to choosing appropriate biologic agents. BioDrugs 30(2):105\u2013115. \n                    https:\/\/doi.org\/10.1007\/s40259-016-0164-7","journal-title":"BioDrugs"},{"issue":"8","key":"4406_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/RHU.0000000000000272","volume":"21","author":"DA Albert","year":"2015","unstructured":"Albert DA (2015) Are all biologics the same? Optimal treatment strategies for patients with early rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. J Clin Rheumatol 21(8):398\u2013404. \n                    https:\/\/doi.org\/10.1097\/RHU.0000000000000272","journal-title":"J Clin Rheumatol"},{"issue":"7387","key":"4406_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","volume":"326","author":"F Song","year":"2003","unstructured":"Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326(7387):472. \n                    https:\/\/doi.org\/10.1136\/bmj.326.7387.472","journal-title":"BMJ"},{"key":"4406_CR17","unstructured":"Coleman CI, Phung OJ, Cappelleri JC, Baker WL, Kluger J, White CM, Sobieraj DM (2012) In: Use of mixed treatment comparisons in systematic reviews. AHRQ methods for effective health care. Rockville (MD)"},{"key":"4406_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/OARRR.S138830","volume":"9","author":"AS Barhamain","year":"2017","unstructured":"Barhamain AS, Magliah RF, Shaheen MH, Munassar SF, Falemban AM, Alshareef MM, Almoallim HM (2017) The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. Open Access Rheumatol 9:139\u2013150. \n                    https:\/\/doi.org\/10.2147\/OARRR.S138830","journal-title":"Open Access Rheumatol"},{"key":"4406_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. \n                    https:\/\/doi.org\/10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"issue":"3","key":"4406_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"key":"4406_CR21","doi-asserted-by":"publisher","unstructured":"G\u00f8tzsche PC (2000) Why we need a broad perspective on meta-analysis: it may be crucially important for patients. 321(7261):585\u2013586. \n                    https:\/\/doi.org\/10.1136\/bmj.321.7261.585","DOI":"10.1136\/bmj.321.7261.585"},{"issue":"12","key":"4406_CR22","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1002\/art.23055","volume":"56","author":"P Durez","year":"2007","unstructured":"Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, Luyten FP, Corluy L, Houssiau FA, Verschueren P (2007) Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 56(12):3919\u20133927. \n                    https:\/\/doi.org\/10.1002\/art.23055","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4406_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27\u201335. \n                    https:\/\/doi.org\/10.1002\/art.20712","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4406_CR24","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study G (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432\u20133443. \n                    https:\/\/doi.org\/10.1002\/art.20568","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4406_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26\u201337. \n                    https:\/\/doi.org\/10.1002\/art.21519","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4406_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.24106","volume":"59","author":"V Bejarano","year":"2008","unstructured":"Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, Gough A, Green M, McGonagle D, Adebajo A, Jarrett S, Doherty S, Hordon L, Melsom R, Unnebrink K, Kupper H, Emery P, Yorkshire Early Arthritis Register C (2008) Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 59(10):1467\u20131474. \n                    https:\/\/doi.org\/10.1002\/art.24106","journal-title":"Arthritis Rheum"},{"issue":"9636","key":"4406_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","volume":"372","author":"P Emery","year":"2008","unstructured":"Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636):375\u2013382. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)61000-4","journal-title":"Lancet"},{"issue":"1","key":"4406_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2015-209057","volume":"76","author":"P Emery","year":"2017","unstructured":"Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis 76(1):96\u2013104. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-209057","journal-title":"Ann Rheum Dis"},{"issue":"10042","key":"4406_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","volume":"388","author":"JWJ Bijlsma","year":"2016","unstructured":"Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos P, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042):343\u2013355. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)30363-4","journal-title":"Lancet"},{"issue":"7","key":"4406_CR30","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/annrheumdis-2016-210561","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S (2017) Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Ann Rheum Dis 76(7):1279\u20131284. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210561","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4406_CR31","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/ard.2008.101121","volume":"68","author":"R Westhovens","year":"2009","unstructured":"Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68(12):1870\u20131877. \n                    https:\/\/doi.org\/10.1136\/ard.2008.101121","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4406_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barre E, Karyekar CS, Wong DA, Huizinga TW (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74(1):19\u201326. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-206106","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4406_CR33","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, Ostergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B (2016) Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 75(6):1024\u20131033. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-208267","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4406_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","volume":"70","author":"PP Tak","year":"2011","unstructured":"Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM, Investigators I (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1):39\u201346. \n                    https:\/\/doi.org\/10.1136\/ard.2010.137703","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4406_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","volume":"73","author":"M Schiff","year":"2014","unstructured":"Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R (2014) Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73(1):86\u201394. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-203843","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4406_CR36","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","volume":"72","author":"J Detert","year":"2013","unstructured":"Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Kruger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Hohne-Zimmer V, Egerer K, Buttgereit F, Burmester GR (2013) Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 72(6):844\u2013850. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2012-201612","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4406_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS (2013) Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72(1):64\u201371. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2011-201247","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4406_CR38","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"P Emery","year":"2009","unstructured":"Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272\u20132283. \n                    https:\/\/doi.org\/10.1002\/art.24638","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4406_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","volume":"48","author":"M Soubrier","year":"2009","unstructured":"Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 48(11):1429\u20131434. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kep261","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"4406_CR40","doi-asserted-by":"publisher","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","volume":"2","author":"V Strand","year":"2016","unstructured":"Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G (2016) Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL start trial. RMD Open 2(2):e000308. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2016-000308","journal-title":"RMD Open"},{"issue":"10093","key":"4406_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS, investigators OS (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","journal-title":"Lancet"},{"issue":"3","key":"4406_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69(3):506\u2013517. \n                    https:\/\/doi.org\/10.1002\/art.39953","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"4406_CR43","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P (2014) A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Ann Rheum Dis 73(6):1027\u20131036. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-204882","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4406_CR44","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernandez L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R (2017) 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis 76(6):948\u2013959. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210602","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4406_CR45","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/annrheumdis-2018-213035","volume":"77","author":"XM Teitsma","year":"2018","unstructured":"Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel A, Petho-Schramm A, Borm MEA, van Laar JM, Lafeber F, Bijlsma JWJ (2018) Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. Ann Rheum Dis 77(9):1261\u20131267. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2018-213035","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4406_CR46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.autrev.2012.11.009","volume":"12","author":"V Modena","year":"2013","unstructured":"Modena V, Bianchi G, Roccatello D (2013) Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 12(8):835\u2013838. \n                    https:\/\/doi.org\/10.1016\/j.autrev.2012.11.009","journal-title":"Autoimmun Rev"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-04406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-04406-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-04406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:12:26Z","timestamp":1578597146000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-04406-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4406"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-04406-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"30 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}